real-time news and commentary for investors
Monday, Mar 25
Coronado Biosciences (CNDO +4.1%) moves up today after Canaccord initated coverage with a Buy...
Coronado Biosciences (CNDO +4.1%) moves up today after Canaccord initated coverage with a Buy rating and an $18 price target. Canaccord says it's ecouraged by Phase 2 trials for Trichuris suis ova, a biologic composed of pig whipworm eggs being tested for the treatment of Crohn's disease. The firm notes that the drug has a novel mechanism, and physician feedback indicates a high likelihood of success for the upcoming data, which could be an important catalyst for the stock in H2.